304 related articles for article (PubMed ID: 12542895)
41. [Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance].
Zhou ZX; Qiang H; Ma AQ; Chen H; Zhou P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Apr; 31(2):258-62. PubMed ID: 16706128
[TBL] [Abstract][Full Text] [Related]
42. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
[TBL] [Abstract][Full Text] [Related]
43. Autoantibody against, malondialdehyde-modified low density lipoprotein in patients with non-diabetic unstable angina: a potential role in immunologic reaction of plaque instability.
Kwon KH; Kwon HM; Hong BK; Kim DS; Lee JY; Ryu SK; Park BE; Park HY; Kim JH; Yoon YW; Cho SY; Kim HS
Yonsei Med J; 2002 Apr; 43(2):203-10. PubMed ID: 11971214
[TBL] [Abstract][Full Text] [Related]
44. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia.
Bayhan G; Koçyigit Y; Atamer A; Atamer Y; Akkus Z
Gynecol Endocrinol; 2005 Jul; 21(1):1-6. PubMed ID: 16048794
[TBL] [Abstract][Full Text] [Related]
45. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.
Sjögren P; Fredrikson GN; Samnegard A; Ericsson CG; Ohrvik J; Fisher RM; Nilsson J; Hamsten A
Eur Heart J; 2008 Sep; 29(18):2218-26. PubMed ID: 18664466
[TBL] [Abstract][Full Text] [Related]
46. [Changes in serum malondialdehyde-modified low-density lipoprotein in patients with acute myocardial infarction and stable angina pectoris treated by coronary angioplasty].
Araki T; Kanaya H; Shimizu M; Mabuchi H; Kitayama M; Kanemitsu S; Takekoshi N;
J Cardiol; 2001 Aug; 38(2):55-60. PubMed ID: 11525110
[TBL] [Abstract][Full Text] [Related]
47. [Lipoprotein particles LpA-I, LpA-I: A-II and LpB in coronary artery disease].
Calvo C; Olmos A; Ulloa N; Bustos A; Toledo L; Durán D; Naveas R
Rev Med Chil; 2000 Jan; 128(1):9-16. PubMed ID: 10883517
[TBL] [Abstract][Full Text] [Related]
48. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
Tanaga K; Bujo H; Inoue M; Mikami K; Kotani K; Takahashi K; Kanno T; Saito Y
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):662-6. PubMed ID: 11950707
[TBL] [Abstract][Full Text] [Related]
49. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis.
Fornasieri A; Perugini C; Seccia M; Napodano P; D'Amico G; Bellomo G
J Nephrol; 2002; 15(4):349-57. PubMed ID: 12243363
[TBL] [Abstract][Full Text] [Related]
50. Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease.
Ekmekçi H; Işler I; Sönmez H; Gürel C; Ciftçi O; Ulutin T; Kökoğlu E; Domaniç N; Dirican A
Thromb Res; 2006; 117(3):249-54. PubMed ID: 16378831
[TBL] [Abstract][Full Text] [Related]
51. Sialic acid and oxidizability of lipid and proteins and antioxidant status in patients with coronary artery disease.
Serdar Z; Yeşilbursa D; Dirican M; Sarandöl E; Serdar A
Cell Biochem Funct; 2007; 25(6):655-64. PubMed ID: 17006879
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease.
Soltesz P; Veres K; Laczik R; Der H; Csipo I; Timar O; Szomjak E; Szegedi G; Szodoray P
Thromb Haemost; 2007 Aug; 98(2):413-9. PubMed ID: 17721625
[TBL] [Abstract][Full Text] [Related]
53. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
[TBL] [Abstract][Full Text] [Related]
54. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
Sposito AC; Lemos PA; Santos RD; Hueb W; Vinagre CG; Quintella E; Carneiro O; Chapman MJ; Ramires JA; Maranhão RC
J Am Coll Cardiol; 2004 Jun; 43(12):2225-32. PubMed ID: 15193684
[TBL] [Abstract][Full Text] [Related]
55. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis.
Viigimaa M; Abina J; Zemtsovskaya G; Tikhaze A; Konovalova G; Kumskova E; Lankin V
Blood Press; 2010 Jun; 19(3):164-8. PubMed ID: 20429692
[TBL] [Abstract][Full Text] [Related]
56. Immunodetection of modified lipoproteins in plasma and arterial walls of patients with coronary heart disease.
Sima A; Stancu C; Starodub O; Cristea C; Simionescu M
Rom J Intern Med; 1997; 35(1-4):29-38. PubMed ID: 9562650
[TBL] [Abstract][Full Text] [Related]
57. Prooxidant-antioxidant balance and antioxidized LDL antibody level values and cardiac function in patients with coronary artery disease.
Rahsepar AA; Mirzaee A; Moodi F; Moohebati M; Tavallaie S; Eshraghi A; Alavi MS; Khorashadizadeh F; Pourghadamyari H; Paydar R; Amini M; Khojasteh R; Mousavi S; Sahebi M; Ghayour-Mobarhan M; Ferns GA
Cardiology; 2012; 122(4):203-9. PubMed ID: 22854352
[TBL] [Abstract][Full Text] [Related]
58. Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium.
Le NA; Li X; Kyung S; Brown WV
Metabolism; 2000 Oct; 49(10):1271-7. PubMed ID: 11079815
[TBL] [Abstract][Full Text] [Related]
59. [Immune response against modified low-density lipoproteins in patients with non-insulin-dependent diabetes mellitus].
González M; Rojas N; Durán D; Schade A; Campos R; Milos C
Rev Med Chil; 1997 Aug; 125(8):879-85. PubMed ID: 9567390
[TBL] [Abstract][Full Text] [Related]
60. The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically healthy men.
Fagerberg B; Bokemark L; Hulthe J
Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):227-35. PubMed ID: 11831108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
